Oric Pharmaceuticals (ORIC) Return on Capital Employed (2020 - 2026)
Oric Pharmaceuticals' (ORIC) quarterly Return on Capital Employed came in at 37.01% in Q1 2026, up 2386.0% YoY from 1.49% in Q1 2025, and down 3.42% on a QoQ basis from 35.78% in Q4 2025.
Oric Pharmaceuticals (ORIC) Return on Capital Employed (2020 - 2026) Analysis & Trends
Oric Pharmaceuticals (ORIC) has 7 years of Return on Capital Employed data on file, last reported at 37.01% in Q1 2026.
- Quarterly Return on Capital Employed rose 2386.0% year-over-year to 37.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 37.01% (up 2386.0% YoY) and the FY2025 annual result came in at 44.54%, up 1545.0% from the prior year.
- Return on Capital Employed retreated to 37.01% in Q1 2026, from 35.78% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 31.11% in Q1 2022 to a low of 60.87% in Q1 2025.
- A 5-year average of 42.22% and a median of 40.13% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed slumped 2100 bps — and 2026, when it soared 2386 bps.
- Tracing ORIC's Return on Capital Employed over 5 years: stood at 40.39% in 2022, then slipped by 13 bps to 45.64% in 2023, then retreated by 19 bps to 54.28% in 2024, then surged by 34 bps to 35.78% in 2025, then dropped by 3 bps to 37.01% in 2026.
- The last three Return on Capital Employed figures came in at 37.01% (Q1 2026), 35.78% (Q4 2025), and 40.13% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Oric Pharmaceuticals | 1.44 Bn | 1.44 Bn | - | -39.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -39.04% |
| Mar 31, 2026 | -37.01% |
| Dec 31, 2025 | -35.78% |
| Sep 30, 2025 | -40.13% |
| Jun 30, 2025 | -54.07% |
| Mar 31, 2025 | -60.87% |
| Dec 31, 2024 | -54.28% |
| Sep 30, 2024 | -45.80% |
| Jun 30, 2024 | -39.06% |
| Mar 31, 2024 | -39.87% |
| Dec 31, 2023 | -45.64% |
| Sep 30, 2023 | -38.42% |
| Jun 30, 2023 | -40.25% |
| Mar 31, 2023 | -42.42% |
| Dec 31, 2022 | -40.39% |
| Sep 30, 2022 | -39.25% |
| Jun 30, 2022 | -33.43% |
| Mar 31, 2022 | -31.11% |
| Dec 31, 2021 | -27.08% |
| Sep 30, 2021 | -30.20% |